9 recruiting, 4 completed, 3 not yet recruiting, 3 withdrawn. 11 Phase 2, 6 Phase 3, 1 Early Phase 1, 1 Phase 1, 1 Phase 4.
Follow Sobi, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Severe Hepatitis Intervention With Emapalumab for Liver Disease Emapalumab - Hepatitis | Phase 2 | Not yet recruiting | Children's Healthcare of Atlanta | 28 | 2026-09-01 | 2026-08-04 |
| A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment Avatrombopag 20 mg Oral Tablet - Aplastic Anemia | Phase 2 / Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 26 | 2026-07-31 | 2026-08-26 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Not yet recruiting | John Mascarenhas | 26 | 2026-05-04 | 2026-03-18 |
| Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients Emapalumab 3 mg/kg, Emapalumab 10 mg/kg - Hematopoietic Stem Cell Transplantation, Graft Failure | Early Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-01-07 | 2026-01-22 |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia Pacritinib, Hydroxyurea - Leukemia, Myelomonocytic, Chronic | Phase 2 | Recruiting | Theradex | 66 | 2026-01-01 | 2026-08-18 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine and Epcoritamab - Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL) | Phase 2 | Recruiting | Universität Münster | 120 | 2025-10-31 | 2026-07-30 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Pacritinib in CMML Pacritinib, Azacitidine - Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Douglas Tremblay | 26 | 2024-09-18 | 2026-08-11 |
| A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia Emapalumab - Cytopenia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 32 | 2024-07-05 | 2026-08-07 |
| A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Emapalumab, Fludarabine and Dexamethasone, Allogeneic hematopoietic stem cell transplant (allo-HCT) - Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | Joseph Oved | 39 | 2023-03-15 | 2026-06-02 |
| Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant Avatrombopag - Platelet Disorder | Phase 2 | Withdrawn | Ayman Saad | 2022-12-01 | 2021-12-09 | |
| Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP Avatrombopag Oral Tablet - Immune Thrombocytopenia | Phase 3 | Completed | Sobi, Inc. | 19 | 2022-06-15 | 2026-06-03 |
| INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) Hemophagocytic Lymphohistiocytoses | Recruiting | Children's Hospital Medical Center, Cincinnati | 200 | 2021-12-31 | 2026-02-24 | |
| Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months Avatrombopag 20 mg Oral Tablet - Immune Thrombocytopenia | Phase 3 | Withdrawn | Sobi, Inc. | 2021-10-14 | 2021-10-22 | |
| Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim Avatrombopag Oral Tablet - Immune Thrombocytopenia | Phase 4 | Completed | Sobi, Inc. | 60 | 2021-03-15 | 2025-01-16 |
| Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months Avatrombopag, Placebo - Immune Thrombocytopenia | Phase 3 | Completed | Sobi, Inc. | 75 | 2021-03-05 | 2026-06-03 |
| Avatrombopag for Thrombocytopenia in People With Cancer Avatrombopag - Thrombocytopenia, Cancer | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-05-27 | 2020-12-08 | |
| Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers Avatrombopag, Placebo Oral Tablet - Chemotherapy-induced Thrombocytopenia | Phase 3 | Completed | Sobi, Inc. | 122 | 2018-10-12 | 2023-09-28 |
| Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure Avatrombopag - Thrombocytopenia | Terminated | Sobi, Inc. | 50 | 2018-07-02 | 2024-10-21 |
Showing 20 of 21. Sign in to see all of them.
Thrombocytopenia (5) · Purpura, Thrombocytopenic, Idiopathic (4) · Leukemia, Myelomonocytic, Chronic (2) · Primary Myelofibrosis (2) · Anemia (1) · Anemia, Aplastic (1) · Blast Crisis (1) · Blood Platelet Disorders (1) · Bone Marrow Failure Disorders (1) · Bone Marrow Neoplasms (1) · Cytopenia (1) · Disease (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Hepatitis (1)
avatrombopag (10) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (4) · Emapalumab (4) · Tablets (2) · Azacitidine (1) · Dexamethasone (1) · Hydroxyurea (1) · Stem Cell Transplantation (1) · fludarabine (1) · loncastuximab tesirine (1) · selinexor (1)
United States (15) · Germany (2) · Hungary (2) · Poland (2) · Russia (2) · Ukraine (2) · United Kingdom (2) · China (1) · France (1) · Japan (1) · Serbia (1) · Turkey (Türkiye) (1)
Abdulraheem Yacoub, MD (1) · Anthony Sabulski, MD (1) · Ayman Saad, MB/BCH (1) · Douglas Tremblay, MD (1) · Gerald Soff, MD (1) · John Mascarenhas, MD (1) · Joseph Oved, MD (1) · Michael Jordan, MD (1) · Paolo Strati, MD (1) · Raajit Rampal, MD, PhD (1) · Ruben Mesa, MD, FACP (1) · Shayna Sarosiek, MD (1)
PMID 40101243, PMID 40392465, PMID 40418942, PMID 40828490, PMID 41411046
2023 (1), P01CA108671 (1)